Predicting Low-Risk Prostate Cancer from Transperineal Saturation Biopsies by Pim J. van Leeuwen, Amila Siriwardana, Monique Roobol, Francis Ting, Daan Nieboer, James Thompson, Warick Delprado, Anne-Marie Haynes, Phillip Brenner, Phillip Stricker

“…Men who underwent radical prostatectomy (RP) for clinical stage ≤T2, PSA <10 ng/mL, Gleason score <8 PC, diagnosed by transperineal template-guided saturation biopsy were included. …”
Get full text

Burden of Illness in Prostate Cancer Patients with a Low-to-Moderate Risk of Progression: A One-Year, Pan-European Observational Study by Cesare Selli, Anders Bjartell, Javier Burgos, Matthew Somerville, Juan-Manuel Palacios, Laure Benjamin, Libby Black, Ramiro Castro

“…The most frequently used initial treatment was radical prostatectomy (71% of patients). QLQ-PR25 urinary symptoms subscale score was significantly increased at 3 months (P<0.001), indicating that urinary symptoms worsened after treatment. …”
Get full text

Correlation of clinically significant prostate cancer sites across multiparametric MRI, prostate biopsy, and whole-mount pathology for optimal prostate biopsy strategy by Matteo Pacini, Alessandro Zucchi, Riccardo Morganti, Filippo Dazzi, Antonio Luigi Pastore, Fabio Maria Valenzi, Andrea Fuschi, Yazan al Salhi, Gianluca Giannarini, Vincenzo Ficarra, Alchiede Simonato, Petar Antonov, Pinuccia Faviana, Riccardo Bartoletti

“…Abstract Data from patients with suspicious lesions on multiparametric magnetic resonance (mpMRI) and a diagnosis of clinically significant prostate cancer (csPCa) who underwent radical prostatectomy (RP) were collected. The aim was to compare csPCa sites identified through whole-mount pathological analysis (WMA) after RP with PI-RADS ≥ 3 lesions identified on mpMRI, and with csPCa foci detected through targeted-biopsy (TB) or combined targeted + systematic biopsy (TSB). …”
Get full text

The Impact of Atorvastatin on Intraprostatic Biomarkers – Prognostic Value of 3LS-score – Follow-up of ESTO1-Trial by Eemil Lehtonen, Maiju Vertanen, Heimo Syvälä, Teemu Tolonen, Seppo Auriola, Teuvo Tammela, Aino Siltari, Teemu Murtola

“…Methods: The ESTO1 trial randomized 158 statin-naïve PCa patients to receive high-dose atorvastatin (80 mg daily) or placebo before prostatectomy. Long term outcomes were assessed for 102 patients through medical records review. …”
Get full text

Evaluating the feasibility of AI-predicted bpMRI image features for predicting prostate cancer aggressiveness: a multi-center study by Kexin Wang, Ning Luo, Zhaonan Sun, Xiangpeng Zhao, Lilan She, Zhangli Xing, Yuntian Chen, Chunlei He, Pengsheng Wu, Xiangpeng Wang, ZiXuan Kong

“…Materials and methods A total of 878 PCa patients from 4 hospitals were retrospectively collected, all of whom had pathological results after radical prostatectomy (RP). A pre-trained AI algorithm was used to select suspected PCa lesions and extract lesion features for model development. …”
Get full text

Use of erectile dysfunction treatments after prostate cancer treatment and their perceived impact on men’s sex life: an analysis of patient reported outcome survey data by Megan Charlick, Tenaw Tiruye, Kerry Ettridge, Michael O’Callaghan, Alex Jay, Kerri Beckmann

“…Oral medications were more likely to be used at three-months (odds ratio [OR] = 2.48; 95% confidence interval [95%CI] = 1.88–3.27) and six-months (OR = 2.10; 95%CI = 1.63–2.27) than at 12-months post-treatment, and among men from higher socioeconomic areas (OR = 2.41; 95%CI = 1.47–3.93, highest vs. lowest quintile), and following prostatectomy (OR = 4.37; 95%CI = 2.92–6.42), and less likely among older men (OR = 0.08; 95%CI = 0.05–0.13, < 60yrs vs. 70-79yrs). …”
Get full text

The Role of Immunohistochemistry for AMACR/p504s and p63 in Distinguishing Prostate Cancer from Benign Prostate Tissue Samples in Botswana by Ramatlho P, Rugemalila MM, Tawe L, Pain D, Choga OT, Ndlovu AK, Koobotse MO, Lal P, Rebbeck TR, Paganotti GM, Narasimhamurthy M, Kyokunda LT

“…This may potentially validate the use of immunohistochemistry for detecting CaP in Botswana, where it is not routinely utilized.Methods: The study included 69 samples, comprising 5 prostatic chip specimens, 50 core biopsies, and 14 radical prostatectomy specimens. These cases were reviewed and categorized into CaP (49 cases) and benign prostatic hyperplasia (BPH) (20 cases). …”
Get full text

Unveiling <i>DENND2D</i> as a Novel Prognostic Biomarker for Prostate Cancer Recurrence: From Gene to Prognosis by Chi-Fen Chang, Lih-Chyang Chen, Yei-Tsung Chen, Chao-Yuan Huang, Chia-Cheng Yu, Victor C. Lin, Te-Ling Lu, Shu-Pin Huang, Bo-Ying Bao

“…<b>Background:</b> Prostate cancer is a major global health burden, with biochemical recurrence (BCR) following radical prostatectomy affecting 20–40% of patients and posing significant challenges to prognosis and treatment. …”
Get full text

hUC-MSC preserves erectile function by restoring mitochondrial mass of penile smooth muscle cells in a rat model of cavernous nerve injury via SIRT1/PGC-1a/TFAM signaling by Mengbo Yang, Xinda Chen, Ming Zhang, Xiaolin Zhang, Dongdong Xiao, Huiming Xu, Mujun Lu

“…Abstract Background Cavernous nerve injury-induced erectile dysfunction (CNI-ED) is a common complication following radical prostatectomy and severely affects patients’ quality of life. …”
Get full text

The Effect of Steep Trendelenburg Positioning on Retinal Structure and Function during Robotic-Assisted Laparoscopic Procedures by Kazuyuki Hirooka, Kaori Ukegawa, Eri Nitta, Nobufumi Ueda, Yushi Hayashida, Hiromi Hirama, Rikiya Taoka, Yuma Sakura, Mari Yamasaki, Hiroyuki Tsunemori, Mikio Sugimoto, Yoshiyuki Kakehi

“…Robotic-assisted laparoscopic radical prostatectomy (RALP) has become a standard treatment choice for localized prostate cancer. …”
Get full text

Comparison between 18F-DCFPyL PET/MRI-guided ultrasound fusion targeted biopsy and systematic biopsy for tumor detection and grading in selected patients: A prospective randomized... by Shaoxi Niu, Yachao Liu, Liyan Ao, Xiaohui Ding, Xiao Chang, Jinhang Li, Jiajin Liu, Kan Liu, Nanxing Zou, Baixuan Xu, Yong Xu, Baojun Wang, Xu Zhang

“…Patients diagnosed with clinically significant prostate cancer proceeded to radical prostatectomy. The primary outcome was the pathological upgrade rate. …”
Get full text

Biochemical failure-free survival of 18F-rhPSMA-7 and 18F-flotufolastat PET-guided salvage radiotherapy for patients with recurrent prostate cancer by Marco M. E. Vogel, Isabel Rauscher, Jürgen E. Gschwend, Türkay Hekimsoy, Nicola Gabler, Charlotte Olufs, Calogero D’Alessandria, Jan C. Peeken, Stephanie E. Combs, Matthias Eiber

“…We evaluated biochemical failure-free survival (bFS) and overall rates of bFS in 110 evaluable patients with recurrent PC after radical prostatectomy who received SRT. 82 patients received 18F-rhPSMA-7/18F-flotufolastat-PET-guided SRT and 28 received C-SRT. …”
Get full text